Jeff Baxter
Chief Executive Officer presso VBI VACCINES INC.
Patrimonio netto: 12 225 $ in data 31/03/2024
Profilo
Jeffrey R. Baxter è presidente, amministratore delegato e direttore di VBI Vaccines, Inc., amministratore non esecutivo indipendente di Chromadex Corp., presidente, amministratore delegato e direttore di VBI Vaccines (Delaware), Inc. e presidente, amministratore delegato e direttore di Variation Biotechnologies (US), Inc. Fa parte del consiglio di amministrazione di VBI Vaccines, Inc., Chromadex Corp., VBI Vaccines (Delaware), Inc. e Variation Biotechnologies (US), Inc. Baxter è stato precedentemente impiegato come SVP-Finance, Operations, Research & Development di GlaxoSmithKline Plc, come Principal di British American Tobacco plc, come Managing Partner di The Column Group LLC e come Principal di Unilever Plc. Si è laureato alla Thames Valley University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
VBI VACCINES, INC.
0.09% | 27/07/2023 | 20 274 ( 0.09% ) | 12 225 $ | 31/03/2024 |
Posizioni attive di Jeff Baxter
| Società | Posizione | Inizio |
|---|---|---|
| VBI VACCINES INC. | Chief Executive Officer | 01/05/2016 |
Variation Biotechnologies (US), Inc.
 Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Chief Executive Officer | 22/09/2009 |
VBI Vaccines (Delaware), Inc.
 VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Chief Executive Officer | 01/07/2014 |
Precedenti posizioni note di Jeff Baxter
| Società | Posizione | Fine |
|---|---|---|
| CHROMADEX CORPORATION | Director/Board Member | 04/04/2022 |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Chief Investment Officer | 28/02/2009 |
| GSK PLC | Corporate Officer/Principal | 01/07/2006 |
| UNILEVER PLC | Corporate Officer/Principal | - |
| BRITISH AMERICAN TOBACCO P.L.C. | Corporate Officer/Principal | - |
Formazione di Jeff Baxter
| University of West London | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| BRITISH AMERICAN TOBACCO P.L.C. | Consumer Non-Durables |
| UNILEVER PLC | Consumer Non-Durables |
| GSK PLC | Health Technology |
| CHROMADEX CORPORATION | Health Technology |
| VBI VACCINES INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Variation Biotechnologies (US), Inc.
Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
VBI Vaccines (Delaware), Inc.
VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Health Technology |
- Borsa valori
- Insiders
- Jeff Baxter
